CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

X4 Pharmaceuticals, Inc

XFOR
$312MSmall Cap

Next catalyst

Phase 3September 2027

Mavorixafor

WHIM Syndrome

Get an email about XFOR's next catalysts

Track X4 Pharmaceuticals (XFOR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 3Next

Mavorixafor Phase 3 Est. Readout

September 2027~Mavorixafor176

Estimated primary completion for Mavorixafor trial (NCT06056297) in Neutropenia. Topline data typically follows completion by weeks to months.

Source

How XFOR's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)πŸ‡ΊπŸ‡ΈNorth AmericaBOSTON143 employees
Drug Pipeline

Frequently asked questions

What is in X4 Pharmaceuticals, Inc's drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in X4 Pharmaceuticals, Inc's (XFOR) pipeline across Phase 3, Phase 2. Its lead program is Mavorixafor (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is X4 Pharmaceuticals, Inc's next FDA catalyst?β†’

X4 Pharmaceuticals, Inc's (XFOR) next tracked catalyst is a Phase 3 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track XFOR biotech catalysts?β†’

Add XFOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow X4 Pharmaceuticals, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply